tsh biopharmoration Ltd - Asset Resilience Ratio
tsh biopharmoration Ltd (8432) has an Asset Resilience Ratio of 20.36% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check tsh biopharmoration Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how tsh biopharmoration Ltd's Asset Resilience Ratio has changed over time. See tsh biopharmoration Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down tsh biopharmoration Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is tsh biopharmoration Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$377.13 Million | 20.36% |
| Total Liquid Assets | NT$377.13 Million | 20.36% |
Asset Resilience Insights
- Good Liquidity Position: tsh biopharmoration Ltd maintains a healthy 20.36% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
tsh biopharmoration Ltd Industry Peers by Asset Resilience Ratio
Compare tsh biopharmoration Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for tsh biopharmoration Ltd (2017–2024)
The table below shows the annual Asset Resilience Ratio data for tsh biopharmoration Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.77% | NT$309.01 Million ≈ $9.74 Million |
NT$1.84 Billion ≈ $58.04 Million |
+2.81pp |
| 2023-12-31 | 13.97% | NT$195.54 Million ≈ $6.16 Million |
NT$1.40 Billion ≈ $44.10 Million |
-8.81pp |
| 2022-12-31 | 22.78% | NT$326.86 Million ≈ $10.30 Million |
NT$1.44 Billion ≈ $45.21 Million |
-7.28pp |
| 2021-12-31 | 30.06% | NT$351.52 Million ≈ $11.07 Million |
NT$1.17 Billion ≈ $36.84 Million |
+3.30pp |
| 2020-12-31 | 26.76% | NT$328.97 Million ≈ $10.36 Million |
NT$1.23 Billion ≈ $38.73 Million |
-9.51pp |
| 2019-12-31 | 36.27% | NT$458.39 Million ≈ $14.44 Million |
NT$1.26 Billion ≈ $39.82 Million |
-5.76pp |
| 2018-12-31 | 42.03% | NT$512.94 Million ≈ $16.16 Million |
NT$1.22 Billion ≈ $38.45 Million |
+10.83pp |
| 2017-12-31 | 31.20% | NT$399.90 Million ≈ $12.60 Million |
NT$1.28 Billion ≈ $40.38 Million |
-- |
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more